{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": 14.3492775, "regularMarketPrice": 10.28, "exchange": "NMS", "shortName": "Y-mAbs Therapeutics, Inc.", "longName": "Y-mAbs Therapeutics, Inc.", "messageBoardId": "finmb_378585331", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "bookValue": 2.469, "fiftyDayAverage": 5.359, "fiftyDayAverageChange": 4.9209995, "fiftyDayAverageChangePercent": 0.9182682, "twoHundredDayAverage": 8.17915, "twoHundredDayAverageChange": 2.10085, "twoHundredDayAverageChangePercent": 0.25685436, "marketCap": 449003648, "forwardPE": -13.012657, "priceToBook": 4.1636286, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.6 - Hold", "tradeable": false, "cryptoTradeable": false, "earningsTimestamp": 1683637200, "earningsTimestampStart": 1691438400, "earningsTimestampEnd": 1691784000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.9, "epsForward": -0.79, "epsCurrentYear": -1.02, "priceEpsCurrentYear": -10.078431, "sharesOutstanding": 43677400, "firstTradeDateMilliseconds": 1537536600000, "priceHint": 2, "preMarketChange": 0.3000002, "preMarketChangePercent": 2.91829, "preMarketTime": 1684224000, "preMarketPrice": 10.58, "regularMarketChange": 1.29, "regularMarketTime": 1684180805, "regularMarketDayHigh": 10.95, "regularMarketDayRange": "9.37 - 10.95", "regularMarketDayLow": 9.37, "regularMarketVolume": 909086, "regularMarketPreviousClose": 8.99, "bid": 0.0, "ask": 0.0, "bidSize": 8, "askSize": 14, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 9.64, "averageDailyVolume3Month": 768278, "averageDailyVolume10Day": 586340, "fiftyTwoWeekLowChange": 7.58, "fiftyTwoWeekLowChangePercent": 2.8074074, "fiftyTwoWeekRange": "2.7 - 20.48", "fiftyTwoWeekHighChange": -10.2, "fiftyTwoWeekHighChangePercent": -0.49804688, "fiftyTwoWeekLow": 2.7, "fiftyTwoWeekHigh": 20.48, "marketState": "PRE", "displayName": "Y-mAbs Therapeutics", "symbol": "YMAB"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "230 Park Avenue", "address2": "Suite 3350", "city": "New York", "state": "NY", "zip": "10169", "country": "United States", "phone": "646 885 8505", "website": "https://www.ymabs.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Gad", "age": 52, "title": "Founder, Interim CEO, Pres, Head of Bus. Devel. & Strategy and Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 1047496, "fmt": "1.05M", "longFmt": "1,047,496"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Bo  Kruse", "age": 50, "title": "Exec. VP, Sec., Treasurer & CFO", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": {"raw": 685021, "fmt": "685.02k", "longFmt": "685,021"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Susan  Smith", "age": 51, "title": "Sr. VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 710000, "fmt": "710k", "longFmt": "710,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Joris Wiel Jan Wilms", "age": 48, "title": "Sr. VP & COO", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Torben  Lund-Hansen M.Sc., Ph.D.", "age": 71, "title": "Sr. VP & CTO", "yearBorn": 1951, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Steen  Lisby M.D., M.Sc.", "age": 58, "title": "Sr. VP & Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Vignesh  Rajah M.B.A., MBBS", "age": 57, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 4, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}